VRCI.L Stock Analysis
VR
Uncovered
Verici Dx Plc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Verici Dx Plc operates as a developer of advanced clinical diagnostics in organ transplant. The company is headquartered in Franklin, Tennessee and currently employs 14 full-time employees. The company went IPO on 2020-11-03. The firm is a developer of clinical diagnostics for organ transplant. The company is focused on the kidney transplantation market. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The firm's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The firm develops tests to understand how a patient is responding to organ transplants. The firm's products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The firm's subsidiary is Verici Dx Inc.